Compare Crispr Therapeutics AG (CRSP) vs Realty Income Corp (O) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Realty Income Corp — how do they compare? Crispr Therapeutics AG trades at $53.67 (market cap $5.23B), while Realty Income Corp trades at $62.13 (market cap $58.56B). The key difference: Realty Income Corp is far larger — about 11.2× Crispr Therapeutics AG's market cap, and Realty Income Corp pays a 5.25% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | O | |
|---|---|---|
Market Cap | $5.23B | $58.56B |
Sector | Health | Real Estate |
52-Week High | $76.78 | $67.56 |
52-Week Low | $44.34 | $55.93 |
Enterprise Value | $3.65B | $89.19B |
Dividend Yield | — | 5.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $53.51, down slightly by 0.02% today. The stock shows bullish technical signals with strong support at $53 and resistance at $54. Fundamentally, the company reports widening losses with a net income margin of -4,101.26% in 2025, though Q2 2026 earnings beat expectations. Analyst sentiment remains positive with a consensus price target of $82.67, driven by robust CASGEVY sales growth and pipeline advancements.
Outlook: CRSP offers significant upside potential from gene-editing therapeutics, but high cash burn and negative profitability pose risks. Investment appeal hinges on successful clinical trials and market expansion of approved therapies, balanced against financial sustainability concerns in a competitive biotech landscape.
Realty Income (O) trades at $61.89, down 0.99% for the day, with a bearish technical signal from moving averages despite oversold RSI readings. The company reported Q2 2026 EPS of $0.37, missing the $0.3977 estimate, but raised full-year AFFO guidance. Recent news highlights a $875 million convertible notes offering and a $6 billion hyperscale data center joint venture, supporting growth initiatives amid a 98.8% portfolio occupancy rate.
Outlook remains supported by dividend growth—115 consecutive quarterly increases—and a $10 billion investment target, though elevated debt levels and interest rate sensitivity pose risks. Analysts maintain a consensus price target of $67.29, implying ~9% upside, with 41% buy ratings reflecting cautious optimism for the REIT's income stability and expansion into data centers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Realty Income Corp
Realty Income owns roughly 11,400 properties, most of which are freestanding, single-tenant, triple-net-leased retail properties. Its properties are located in 49 states and Puerto Rico and are leased to 250 tenants from 47 industries. Recent acquisitions have added industrial, office, manufacturing, and distribution properties, which make up roughly 17% of revenue.
Read more on O →
